Organic Letters
Letter
(10) (a) Fustero, S.; Moscardo,
́
J.; San
́
chez-Rosello,
́
M.; Rodríguez,
ASSOCIATED CONTENT
* Supporting Information
Experimental procedures and NMR spectra for all new
compounds as well as crystallographic data (CIF) for
compounds 6f and 9a. This material is available free of charge
■
E.; Barrio, P. Org. Lett. 2010, 12, 5494. (b) Fustero, S.; Herrera, L.;
Lazaro, R.; Rodríguez, E.; Maestro, M. A.; Mateu, N.; Barrio, P.
Chem.Eur. J. 2013, 19, 11776. (c) Fustero, S.; Ibanez, I.; Barrio, P.;
S
́
̃
́
Maestro, M. A.; Catalan, S. Org. Lett. 2013, 15, 832.
(11) (a) Burke, M. D.; Schreiber, S. L. Angew. Chem., Int. Ed. 2004,
43, 46. (b) Spring, D. R. Org. Biomol. Chem. 2003, 1, 3867.
(c) Schreiber, S. L. Science 2000, 287, 1964.
(12) To the best of our knowledge, only one example of an allylation
reaction (racemic) of an o-iodobenzylidenimine has been described;
see: Hart, D. J.; Kanai, K.-I.; Thomas, D. G.; Yang, T. K. J. Org. Chem.
1983, 48, 289.
(13) In addition, this strategy allows us to obtain homogeneous dr in
the final products regardless of the alkyne used. We have observed that
the reversed reaction sequence results in variable dr’s (2:1 to 10:1)
depending on the substitution at the alkyne.
AUTHOR INFORMATION
Corresponding Authors
■
Notes
The authors declare no competing financial interest.
(14) For recent reports on the use of CF3-alkynes in the
intermolecular PKR, see: (a) Aiguabella, N.; del Pozo, C.;
Verdaguer, X.; Fustero, S.; Riera, A. Angew. Chem., Int. Ed. 2013,
125, 5463. (b) Kizirian, J.-C.; Aiguabella, N.; Pesquer, A.; Fustero, S.;
Bello, P.; Verdaguer, X.; Riera, A. Org. Lett. 2010, 12, 5620.
(15) The TMS precursor failed to cyclized under a number of
reaction conditions.
ACKNOWLEDGMENTS
We thank the Spanish Ministerio de Ciencia e Innovacion
■
́
(CTQ2010-19774-C02-01, CTQ2011-23620) and the General-
itat Valenciana (PROMETEO/2010/061) and Generalitat
Catalana (2009SGR-00901) for their financial support. P.B.,
R.L., and N.A. thank the Spanish government for a Juan de la
Cierva contract and predoctoral fellowships, respectively.
Technical and human support provided by SGIker (UPV/
EHU, MINECO, GV/EJ, ERDF, and ESF) is gratefully
acknowledged.
(16) For some recent reports on aminosteroids, see: (a) Slavíkova,
́
B.; Bujons, J.; Matyas, L.; Vidal, M.; Babot, Z.; Kristofíkova, Z.; Sunol,
́
́
̃
C.; Kasal, A. J. Med. Chem. 2013, 56, 2323. (b) Fousteris, M. A.;
Schubert, U.; Roell, D.; Roediger, J.; Bailis, N.; Nikolaropoulos, S. S.;
Baniahmad, A.; Giannis, A. Bioorg. Med. Chem. 2010, 18, 6960.
(c) Keyzers, R. A.; Daoust, J.; Davies-Coleman, M. T.; Van Soest, R.;
Balgi, A.; Donohue, E.; Roberge, M.; Andersen, R. J. Org. Lett. 2008,
10, 2959. (d) Khan, S. N.; Kim, B. J.; Kim, H.-S. Bioorg. Med. Chem.
Lett. 2007, 17, 5139.
REFERENCES
■
(1) Ochoa Puentes, C.; Kouznetsov, V. J. Heterocycl. Chem. 2002, 39,
595.
(2) For recent general reviews on asymmetric allylation, see: (a) Yus,
M.; Gonzalez-Gomez, J. C; Foubelo, F. Chem. Rev. 2011, 111, 7774.
́ ́
(b) Ding, H.; Friestad, G. K. Synthesis 2005, 2815. (c) Kennedy, J. W.
J.; Hall, D. G. Angew. Chem., Int. Ed. 2003, 42, 4732.
(3) For recent reviews on asymmetric allylation of imines, see:
(a) Ramadhar, T. R.; Batey, R. A. Synthesis 2011, 1321.
(b) Ramachandran, P. V.; Burhardt, T. E. Pure Appl. Chem. 2006,
78, 1397. (c) Hernandez, E.; Canales, E.; Gonzalez, E.; Soderquist, J.
A. Pure Appl. Chem. 2006, 78, 1389.
(17) For examples of 11-aminosteroids, see: (a) Yang, J.; Weinberg,
R.; Breslow, R. Chem. Commun. 2000, 531. (b) Yang, J.; Breslow, R.
Tetrahedron Lett. 2000, 41, 8073. (c) Campbell, A. C.; Maidment, M.
S.; Pick, J. H.; Woods, G. F. J. Chem. Soc., Perkin Trans. 1 1979, 1936.
(d) Marples, B. A. J. Chem. Soc. C 1968, 3016.
(18) (a) Waldo, J. P.; Zhang, X.; Shi, F.; Larock, R. C. J. Org. Chem.
2008, 73, 6679. (b) Paul, S.; Samanta, S.; Ray, J. K. Tetrahedron Lett.
2010, 51, 5604.
(4) For a recent review about Ellman’s auxiliary, see: Robak, M. T.;
Herbage, M. A.; Ellman, J. A. Chem. Rev. 2010, 110, 3600.
(5) For recent reviews on the Pauson−Khand reaction, see: (a) The
Pauson Khand Reaction. Scope, Variations and Applications; Rios Torres,
R., Ed; Wiley: Chichester, UK, 2012. (b) Lee, H.; Kwong, F. Eur. J.
Org. Chem. 2010, 789. (c) Park, J. H.; Chang, K.; Chung, Y. K. Coord.
Chem. Rev. 2009, 253, 2461. (d) Gibson, S. E.; Mainolfi, N. Angew.
Chem., Int. Ed. 2005, 44, 3022. (e) Blanco-Urgoiti, J.; Anorbe, L.;
Perez-Serrano, L.; Dominguez, G.; Perez-Castells, J. Chem. Soc. Rev.
2004, 33, 32. (f) Pericas, M. A.; Balsells, J.; Castro, J.; Marchueta, I.;
́
Moyano, A.; Riera, A.; Vazquez, J.; Verdaguer, X. Pure Appl. Chem.
2002, 74, 167.
(6) For some recent non-Pauson−Khand methodologies toward the
cylopentenone ring, see: (a) Barluenga, J.; Barrio, P.; Riesgo, L.;
́ ́
Lopez, L. A.; Tomas, M. J. Am. Chem. Soc. 2007, 129, 14422.
(b) Davie, C. P.; Danheiser, R. L. Angew. Chem., Int. Ed. 2005, 44,
5867. (c) Shi, X.; Gorin, D. J.; Toste, F. D. J. Am. Chem. Soc. 2005,
127, 5802. (d) Zhang, L.; Wang, S. J. Am. Chem. Soc. 2006, 128, 1442.
(7) For asymmetric addition/PKR on N-propargyl substrates giving
rise to N-heterocylic-fused cyclopentenones, see: (a) Akullian, L. C.;
Snapper, M. L.; Hoveyda, A. H. Angew. Chem., Int. Ed. 2003, 42, 4244.
(b) Gunter, M.; Gais, H. J. J. Org. Chem. 2003, 68, 8037.
̈
́
(8) Blanco-Urgoiti, J.; Casarrubios, L.; Domínguez, G.; Perez-
Castells, J. Tetrahedron Lett. 2001, 42, 3315.
(9) (a) Fustero, S.; Rodríguez, E.; Herrera, L.; Asensio, A.; Maestro,
M. A.; Barrio, P. Org. Lett. 2011, 13, 6564. (b) Fustero, S.; Lazaro, R.;
́
Herrera, L.; Rodríguez, E.; Mateu, N.; Barrio, P. Org. Lett. 2013, 15,
3770.
D
dx.doi.org/10.1021/ol500142c | Org. Lett. XXXX, XXX, XXX−XXX